UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): ~~December~~September 1912, ~~2022~~2023 (~~December~~September 146, ~~2022~~2023)

Tekla World Healthcare Fund

(Exact name of Registrant as Specified in Its Charter)

Massachusetts	811-23037		47-3910842
(State or other jurisdiction	(Commission File Number)		(I.R.S. Employer
of incorporation)			Identification No.)

100 Federal Street, 19^th Floor
Boston, MA		02110
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (617) 772-8500

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Shares of Beneficial Interest, $0.01 par value		THW		New York Stock Exchange

Item 14.01 -Changes ~~Entry~~in ~~into~~Registrant’s aCertifying ~~Material Definitive Agreement~~Accountant.

~~New~~(a) ~~Distribution~~Resignation ~~and~~of ~~Sub-Placement~~independent ~~Agent~~registered ~~Agreements~~public accounting firm

~~Tekla~~On ~~World~~September ~~Healthcare~~6, ~~Fund~~2023, ~~(NYSE:~~Deloitte ~~THW)~~& ~~(the~~Touche LLP (“~~Fund~~D&T”), ~~has~~the ~~entered~~independent ~~into~~registered apublic ~~distribution~~accounting ~~agreement~~firm (for the ~~“Distribution~~Tekla ~~Agreement”),~~World ~~dated~~Healthcare ~~December 14, 2022, with Foreside~~ Fund ~~Services, LLC~~ (the “~~Foreside~~Fund”), ~~pursuant~~resigned due to ~~which~~an ~~the~~anticipated independence ~~Fund~~issue ~~may~~arising ~~offer~~as ~~and~~a ~~sell~~result ~~common shares~~ of ~~beneficial~~a ~~interest,~~pending ~~par~~transaction ~~value~~between ~~$0.01~~Tekla ~~per share~~Capital ~~(“Common~~Management ~~Shares”)~~LLC ~~having~~and anabrdn ~~aggregate~~Inc. ~~initial~~On ~~offering~~September ~~price of up to $150~~7,~~000,000,~~ ~~from time to time~~2023, ~~through Foreside~~ ~~as agent for~~ the ~~Fund~~Audit ~~for~~Committee of the ~~offer~~Board ~~and sale~~ of ~~Common~~Trustees ~~Shares, in transactions deemed to be “at~~ (the ~~market~~“Board”) asof ~~defined in Rule 415 under~~ the ~~Securities~~Fund ~~Act~~approved ofD&T’s ~~1933, as amended (the “Offering”)~~resignation.

The ~~Offering~~reports ~~is being made pursuant to a prospectus supplement, dated December 14, 2022 and the accompanying prospectus, dated December 6, 2022, each~~ of ~~which~~D&T ~~constitute~~on ~~part of~~ the Fund’s ~~effective~~ ~~shelf~~financial ~~registration~~statements as ~~statement~~of onand ~~Form~~for ~~N-2 (File No. 333-267555) previously filed with~~ the ~~Securities~~two ~~and~~most ~~Exchange~~recent ~~Commission (the~~fiscal ~~“Registration~~years ~~Statement”).~~ended ~~Under~~September ~~the~~30, ~~Investment~~2022 ~~Company~~and ~~Act~~September ~~of 1940~~30, as2021 ~~amended,~~did ~~the~~not ~~Fund~~contain ~~may~~an ~~not~~adverse ~~sell~~opinion ~~any~~or ~~Common Shares~~a atdisclaimer aof ~~price~~opinion, ~~below~~nor ~~the~~were ~~current~~such ~~net~~reports ~~asset~~qualified ~~value~~or ofmodified ~~such~~as ~~Common~~to ~~Shares~~uncertainties, ~~exclusive~~audit ofscope ~~any distributing commission~~ or ~~discount~~accounting principles.

~~Under~~During the ~~Distribution~~Fund’s ~~Agreement,~~two ~~Foreside~~most ~~may enter~~recent ~~into~~fiscal ~~sub-placement~~years ~~agent~~(ended September ~~agreements~~30, ~~with~~2022 ~~one~~and orSeptember ~~more~~30, ~~selected~~2021) ~~dealers.~~and ~~Foreside~~the ~~has~~subsequent ~~entered~~interim ~~into~~period athrough ~~sub-placement~~September ~~agent~~6, ~~agreement~~2023, ~~dated~~ ~~December~~there ~~14,~~were ~~2022~~no “disagreements” (within the ~~“Sub-Placement~~meaning ~~Agent~~of ~~Agreement”~~Item 304(a),(1)(iv) ~~with~~of ~~UBS~~Regulation S-K and the related instructions under the Securities ~~LLC~~Exchange Act of 1934, as amended (the “~~UBS~~Exchange Act”)) ~~relating~~between the Fund and D&T on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of D&T, would have caused ~~Common~~D&T ~~Shares~~to make reference to bethe ~~offered~~subject ~~under~~matter of the ~~Distribution~~disagreements ~~Agreement~~in its reports on the financial statements of the Fund for such years.

~~Pursuant~~Also toduring ~~the~~this ~~Distribution~~same ~~Agreement~~period, ~~the~~there ~~Fund will~~were ~~compensate~~no ~~Foreside~~“reportable events” ~~with~~(within ~~respect~~the tomeaning ~~sales~~ of ~~Common~~Item ~~Shares at~~ 304(a ~~commission rate of~~ )(1~~.00%~~)(v) of ~~the~~Regulation ~~gross~~S-K ~~proceeds~~and of the ~~sale~~related ofinstructions ~~Common Shares. Out of this commission,~~ under the ~~Sub-Placement~~Exchange ~~Agent Agreement, Foreside will compensate UBS at a rate of up to 0~~Act).~~80% of the gross sales proceeds of the sale of the Common Shares sold by UBS.~~

~~Shareholders~~The ~~may~~Fund ~~request~~has ~~free~~provided ~~copies~~D&T with a copy of the ~~prospectus~~foregoing disclosures ~~supplement,~~under ~~accompanying~~Item ~~prospectus,~~4.01 ~~statement~~on ofForm ~~additional~~8-K ~~information,~~prior orto filing it with the ~~Fund’s~~U.S. ~~annual~~Securities and ~~semi-annual~~Exchange ~~reports~~Commission by(“SEC”) ~~calling~~and has requested that D&T furnish to the Fund’s ~~investment~~with ~~adviser,~~a ~~Tekla~~letter ~~Capital~~addressed ~~Management~~to ~~LLC,~~the atSEC ~~(617)~~stating ~~772-8500~~whether orit byagrees ~~writing~~with the ~~Fund~~statements ~~c/o~~made ~~Tekla~~by ~~Capital~~the ~~Management~~Fund in ~~LLC,~~this ~~100~~Item ~~Federal~~4.01 ~~Street,~~on ~~19th~~Form ~~Floor~~8-K. ~~Boston,~~A MAcopy ~~02110,~~of orD&T’s ~~you~~letter, ~~may~~dated ~~obtain~~September a12, ~~copy~~2023, ~~(and~~is ~~other~~attached ~~information~~as ~~regarding~~Exhibit ~~the~~16.1 ~~Fund)~~to ~~from~~this ~~the~~report ~~SEC’s website~~on ~~(http://www~~Form 8-K.~~sec.gov).~~

~~The~~(b) ~~foregoing~~Engagement ~~descriptions~~ of ~~the~~new ~~Distribution Agreement~~independent ~~and~~registered ~~the Sub-Placement Agent Agreement do not purport to be complete and are qualified in their entirety by reference to the~~public ~~full~~accounting text of the Distribution Agreement filed with this report as Exhibit 1.1 and incorporated herein by reference, and the full text of the Sub-Placement Agent Agreement filed with this report as Exhibit 1.2 and incorporated herein by reference.firm

On September 7, 2023, upon the recommendation of the Audit Committee of the Board, the Board approved the engagement of KPMG LLP (“KPMG”) as the independent registered public accounting firm for the Fund for the fiscal year ending September 30, 2023. During the Fund’s two most recent fiscal years (ended September 30, 2022 and September 30, 2021) and the subsequent interim period prior to the engagement of KPMG, neither the Fund, nor anyone on the Fund’s behalf consulted with KPMG regarding (1) the application of accounting principles to a specified transaction, either completed or proposed; (2) the type of audit opinion that might be rendered on the Fund’s financial statements; or (3) the subject of any “disagreement,” as defined in Item 304(a)(1)(iv) of Regulation S-K under the Exchange Act and the instructions thereto, or a “reportable event,” as defined in Item 304(a) (1)(v) of Regulation S-K under the Exchange Act.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

116.1 ~~Distribution~~Letter ~~Agreement~~dated ~~between~~September 12, 2023 from Deloitte & Touche LLP to the ~~Fund~~Securities and ~~Foreside~~Exchange ~~Fund~~Commission ~~Services,~~confirming ~~LLC~~the ~~dated~~disclosures ~~December~~contained ~~14,~~in ~~2022~~Item 4.01 of this report on Form 8-K

~~1.2~~104 ~~Sub-Placement~~Cover ~~Agent~~Page ~~Agreement~~Interactive ~~between~~Data ~~Foreside~~File ~~Fund~~(embedded ~~Services,~~within ~~LLC~~the ~~and~~Inline ~~UBS~~XBRL ~~Securities LLC dated December 14, 2022~~document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	TEKLA WORLD HEALTHCARE FUND
Date: December 19, 2022	By:	/s/ Daniel R. Omstead
Date: September 12, 2023	By:	/s/ Daniel R. Omstead
		Name:	Daniel R. Omstead
		Name: Daniel R. Omstead
		Title:	President
		Title: President

EXHIBIT INDEX

Exhibit No.

Description

16.1

Letter dated September 12, 2023 from Deloitte & Touche LLP to the Securities and Exchange Commission confirming the disclosures contained in Item 4.01 of this report on Form 8-K

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

Filing Compare · abrdn World Healthcare Fund